Ki67是局限性前列腺癌最大随机分次试验中复发的独立预测因子
该研究基于CHHiP随机试验(74 Gy/37次 vs 60 Gy/20次 vs 57 Gy/19次)的匹配病例对照设计,评估Ki67对生化/临床复发(BCR)的预后价值及对分次方案的预测作用。诊断性Ki67不能预测分次方案对BCR的影响,但为强独立预后因素。
要点
- 平均和最大Ki67评分均为BCR的显著独立预测因子
- Ki67与分次方案的交互作用无统计学意义,不能预测分次获益
核心结论
- 诊断性Ki67不能预测不同分次方案对BCR的影响,但为BCR的强独立预后因素。
研究设计与样本
- 匹配病例对照研究,来自比较74 Gy/37次、60 Gy/20次、57 Gy/19次三种分次方案的随机试验。
- 放疗后>2年发生生化/临床失败(BCR)的患者按Gleason评分、前列腺特异性抗原、肿瘤分期和分次方案1:1匹配无复发患者。
- 对诊断性活检标本行Ki67免疫组化染色,采用无权重全局法评分。
- 使用条件logistic回归模型评估平均和最大Ki67评分对BCR风险的预后价值及生物标志物-分次交互作用。
主要发现
- 共纳入173对匹配病例。
- 平均Ki67评分中位数为6.6%(四分位距3.9%-9.8%),最大Ki67评分中位数为11.0%(四分位距7.0%-15.0%)。
- 在校正已确立预后因素的模型中,平均和最大Ki67评分均为BCR的显著预测因子。
- Ki67与分次方案之间的交互作用无统计学意义。
临床怎么用
- 诊断性Ki67可作为局限性前列腺癌放疗后BCR的独立预后标志物,辅助风险分层。
- Ki67目前不能用于指导分次方案的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a randomized trial of 3 radiation therapy fractionation schedules (74 Gy/37 fractions vs 60 Gy/20 fractions vs 57 Gy/19 fractions). METHODS AND MATERIALS: A matched case-control study design was used; patients with biochemical/clinical failure >2 years after radiation therapy (BCR) were matched 1:1 to patients without recurrence using established prognostic factors (Gleason score, prostate-specific antigen, tumor stage) and fractionation schedule. Immunohistochemistry was used to stain diagnostic biopsy specimens for Ki67, which were scored using the unweighted global method. Conditional logistic regression models estimated the prognostic value of mean and maximum Ki67 scores on BCR risk. Biomarker-fractionation interaction terms determined whether Ki67 was predictive of BCR by fractionation. RESULTS: Using 173 matched pairs, the median for mean and maximum Ki67 scores were 6.6% (interquartile range, 3.9%-9.8%) and 11.0% (interquartile range, 7.0%-15.0%) respectively. Both scores were significant predictors of BCR in models adjusted for established prognostic factors. Conditioning on matching variables and age, the odds of BCR were estimated to increase by 9% per 1% increase in mean Ki67 score (odds ratio 1.09; 95% confidence interval 1.04-1.15, P = .001). Interaction terms between Ki67 and fractionation schedules were not statistically significant. CONCLUSIONS: Diagnostic Ki67 did not predict BCR according to fractionation schedule in CHHiP; however, it was a strong independent prognostic factor for BCR.
引用
- Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559283. doi:10.1016/j.ijrobp.2018.01.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。